Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease

A Abbate, S Toldo, C Marchetti, J Kron… - Circulation …, 2020 - Am Heart Assoc
The intracellular sensing protein termed NLRP3 (for NACHT, LRR, and PYD domains-
containing protein 3) forms a macromolecular structure called the NLRP3 inflammasome …

NLRP3 inflammasome inhibitors in cardiovascular diseases

E Mezzaroma, A Abbate, S Toldo - Molecules, 2021 - mdpi.com
Virtually all types of cardiovascular diseases are associated with pathological activation of
the innate immune system. The NACHT, leucine-rich repeat (LRR), and pyrin domain (PYD) …

The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer's disease

N Lonnemann, S Hosseini… - Proceedings of the …, 2020 - National Acad Sciences
Numerous studies demonstrate that neuroinflammation is a key player in the progression of
Alzheimer's disease (AD). Interleukin (IL)-1β is a main inducer of inflammation and therefore …

Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion

IW Tengesdal, DR Menon… - Proceedings of the …, 2021 - National Acad Sciences
Interleukin-1β (IL-1β)–mediated inflammation suppresses antitumor immunity, leading to the
generation of a tumor-permissive environment, tumor growth, and progression. Here, we …

Salvianolic acid B inhibits atherosclerosis and TNF-α-induced inflammation by regulating NF-κB/NLRP3 signaling pathway

Y Zhao, C Shao, H Zhou, L Yu, Y Bao, Q Mao, J Yang… - Phytomedicine, 2023 - Elsevier
Background Inflammation is critical in the pathophysiology of atherosclerosis (AS). The aim
of this study was to investigate the protective effect of salvianolic acid B (Sal B) on AS and to …

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease

J Amo-Aparicio, J Daly, JF Højen… - Journal of …, 2023 - Springer
Background Parkinson's disease (PD) is characterized by a progressive degeneration of
dopaminergic neurons, which leads to irreversible loss of peripheral motor functions. Death …

[HTML][HTML] Discovery of a novel 1, 3, 4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an …

S Gastaldi, C Rocca, E Gianquinto, MC Granieri… - European Journal of …, 2023 - Elsevier
Inspired by the recent advancements in understanding the binding mode of sulfonylurea-
based NLRP3 inhibitors to the NLRP3 sensor protein, we developed new NLRP3 inhibitors …

NLRP3 and cancer: Pathogenesis and therapeutic opportunities

IW Tengesdal, CA Dinarello, C Marchetti - Pharmacology & Therapeutics, 2023 - Elsevier
More than a decade ago IL-1 blockade was suggested as an add-on therapy for the
treatment of cancer. This proposal was based on the overall safety record of anti-IL-1 …

Promise of the NLRP3 inflammasome inhibitors in in vivo disease models

B Das, C Sarkar, VS Rawat, D Kalita, S Deka… - Molecules, 2021 - mdpi.com
Nucleotide-binding oligomerization domain NOD-like receptors (NLRs) are conserved
cytosolic pattern recognition receptors (PRRs) that track the intracellular milieu for the …

Ginger: A complementary approach for management of cardiovascular diseases

NM Roudsari, NA Lashgari, S Momtaz… - Biofactors, 2021 - Wiley Online Library
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide.
Inflammation and oxidative stress play critical roles in progression of various types of CVD …